Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma

• Qiuping Chen,
• Quan Sun,
• Jing Zhang,
• Baixue Li,
• Quansheng Feng,
• Jibin Liu

Affiliations

Qiuping Chen

Quan Sun

Jing Zhang

Baixue Li

Quansheng Feng

Jibin Liu